Treatment of multiresistant Acinetobacter baumannii infections.
Acinetobacter baumannii are non-fermentative, Gram-negative bacilli that cause a large number of nosocomial infections worldwide. They are characterized by frequent multiresistance due to multiple mechanisms. As a consequence, infections caused by strains exhibiting resistance to carbapenems and, sometimes, polymyxins, are regularly observed. Sulbactam, colistin and combinations of different antimicrobials have been reported as new therapeutic approaches for infections caused by resistant A baumannii strains. This review focuses on current and potential new drugs, such as rifampin, tigecycline, antimicrobial peptides, efflux pump resistant and inhibitor drugs, and enzyme inhibitors.
Pachón
Jerónimo
J
Department of Infectious Diseases, Hospital Virgen del Rocio, University of Seville, Sevilla, Spain. jeronimopachon@telefonica.net
Vila
Jordi
J
D000151:Acinetobacter Infections / Q000188:drug therapy*; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects* / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D015394:Molecular Structure; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D004151:Dipeptides; D004791:Enzyme Inhibitors; C419365:phenylalanine arginine beta-naphthylamide; D000078304:Tigecycline; D008911:Minocycline; D012293:Rifampin